Amritanshu Singh, DO
Sleep Medicine · Tulsa, OKNPI 1538695192
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,382 of the $2,817 with a category attached, or 84.6%. 12 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 40.4% of the total. 2025 is the largest year on record at $1,389, more than ten times the $124 reported in 2020.
Across 89 payments — averaging $31.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$1K
- ZOLL Respicardia, Inc.$323
- Harmony Biosciences LLC$282
- Inspire Medical Systems, Inc.$266
- Lilly USA, LLC$141
- Avadel CNS Pharmaceuticals, LLC$140
- plus $527 from 6 others
What the payments were for
- Food & beverage$2,38285%
- Education$43515%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 30 | $1,137 |
| ZOLL Respicardia, Inc. | 11 | $323 |
| Harmony Biosciences LLC | 10 | $282 |
| Inspire Medical Systems, Inc. | 12 | $266 |
| Lilly USA, LLC | 3 | $141 |
| Avadel CNS Pharmaceuticals, LLC | 8 | $140 |
| Novo Nordisk | 2 | $140 |
| AstraZeneca | 1 | $124 |
| Axsome Therapeutics, Inc. | 5 | $98 |
| Azurity Pharmaceuticals, Inc. | 4 | $69 |
| Abbott | 1 | $48 |
| 3b Medical, Inc. | 2 | $48 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- remede System$163
- LOKELMA$124
- Ozempic$121
- XYWAV$113
- ZEPBOUND$109
How this compares
$2,817 in reported general payments places this provider in the 65th percentile of 20 sleep medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Modafinil | 20 | $4,714 |
| Ropinirole Hcl | 25 | $865 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 16 | $617 |
| Eszopiclone | 15 | $263 |
| Trazodone Hcl | 14 | $81 |
| Zaleplon | 44 | $80 |
| Clonazepam | 18 | $66 |
Paid to pharmacies, not to this prescriber.
Other sleep medicine in Tulsa
- Michael NewnamTulsa$284K
- Marilyn CulpTulsa$4K
- Keziah AibangbeeTulsa$2K
- Richard BregmanTulsa$2K
- Christian NguyenTulsa$1K
- Jana LovelessTulsa$250
- Liphard DsouzaTulsa$156
- Tanzeel AwadallaTulsa$53
- Viral DoshiOklahoma City$56K
- Asim MaqsoodOklahoma City$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.